Susquehanna International Group
TRIL

Susquehanna International Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Susquehanna International Group’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-379,627
Closed -$6.67M – 14456
2021
Q3 		$6.67M Buy
379,627
+277,635
+272% +$3.24M ﹤0.01% 3481
2021
Q2 		$989K Sell
101,992
-81,309
-44% -$765K ﹤0.01% 7797
2021
Q1 		$1.97M Sell
183,301
-180,805
-50% -$2.24M ﹤0.01% 5965
2020
Q4 		$5.36M Sell
364,106
-9,914
-3% -$143K ﹤0.01% 3310
2020
Q3 		$5.32M Buy
374,020
+69,704
+23% +$695K ﹤0.01% 2972
2020
Q2 		$2.46M Buy
304,316
+193,430
+174% +$1.2M ﹤0.01% 4127
2020
Q1 		$448K Buy
+110,886
New +$419K ﹤0.01% 7168
2019
Q2 		– Sell
-98,673
Closed -$65K – 11096
2019
Q1 		$65K Buy
+98,673
New +$121K ﹤0.01% 8410
2016
Q4 		– Sell
-25,170
Closed -$372K – 10379
2016
Q3 		$372K Buy
+25,170
New +$290K ﹤0.01% 6582

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's TRIL Position: Q4 2021 in Review

Susquehanna International Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 379,627 shares — an estimated $6.67M sold.

Susquehanna International Group first reported a position in TRIL in Q3 2016 and held it in 9 quarters. The position peaked at $6.67M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Susquehanna International Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Susquehanna International Group sold 379,627 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $6.67M.
  • Susquehanna International Group first reported a position in Trillium Therapeutics Inc. in Q3 2016 and held it in 9 quarters.
  • Susquehanna International Group's Trillium Therapeutics Inc. position peaked at $6.67M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.